First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

This study is a randomized, open, multicenter clinical study to determine whether the addition of sindilizumab to the R-CHOP regimen could improve the objective efficiency of DLBCL patients with P53 mutation with PD-L1 expression and to see if it could prolong patient survival.In this study, patients with P53 mutation with PD-L1 expressing DLBCL were selected to be randomised 1:1 into 2 groups: group A Sindilizumab + R-CHOP and group B R-CHOP. Sindilizumab was administered on day 10 after chemotherapy to avoid interference from prednisone.At the end of 6 cycles, Group A treatment effective maintenance treatment with Sindilizumab for 6 months as indicated.Each patient's tumour tissue was tested for mutations and ctDNA after allocation, and ctDNA and peripheral blood free PD-L1 levels were monitored dynamically during and after treatment.

Inclusion criteria

• Ages≥18 years, ≤ 80 years.
• Patients with primary treatment of DLBCL.
• Histopathologically confirmed diagnosis of diffuse large B-cell lymphoma.
• At least one measurable lesion according to the 2014 Lugano criteria.
• ECOG physical status score of 0, 1 or 2.
• Laboratory tests meet the following criteria unless judged to be due to lymphoma:

• Routine blood tests: (in the absence of growth factor support therapy or blood transfusion within 7 days) haemoglobin ≥ 90 g/L, absolute neutrophil value ≥ 1.5 x 109/L, platelet count ≥ 90 x 109/L.
• Liver biochemistry: serum creatinine ≤ 1.5 x upper limit of normal; total bilirubin ≤ 1.5 x upper limit of normal; glutamate transaminase and glutamic oxalacetic transaminase ≤ 2.5 x upper limit of normal.
• Coagulation: INR and APTT ≤ 2.5 times the upper limit of normal values.
• Consent to use contraception during the trial and for 3 months after its completion.
• Expected survival ≥ 3 months.

Exclusion criteria

• Suffering from other untreated malignant tumours.
• Cardiovascular disease that remains unstable under pharmacological control .
• With severe interstitial lung disease.
• With cognitive impairment.
• Patients with uncontrolled autoimmune disease.
• Presence of uncontrolled active infection.
• Expected survival time < 3 months.
• Lactating women and subjects of childbearing age who do not wish to use contraception.
• With poor adherence or unable to follow up regularly.